Stock Market

articles with this tag

IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops

IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops

Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.

READ ARTICLE

MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence

MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence

Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.

READ ARTICLE

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism

Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.

READ ARTICLE

Revolutionary MedTech Device: a New Frontier in Autism Treatment

Revolutionary MedTech Device: a New Frontier in Autism Treatment

Today’s company has created the first and only regulated medical device for the management of autism in a home setting.

READ ARTICLE

IMC Reports Rising Revenues & Eyes Colitis Market

IMC Reports Rising Revenues & Eyes Colitis Market

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

READ ARTICLE